FOLH1 and metastatic neoplasm: Compared to conventional imaging, PSMA PET radiopharmaceuticals are more accurate, sensitive, and specific at identifying pelvic nodal or distant metastatic disease when used in primary staging, eventually leading to treatment modifications as reported in the ProPSMA study [9].